|
|
|
 
Last trade signal was SELL
at 2008-Dec-22
Price: $0.97
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA(TM), a ragweed allergy immunotherapeutic, that has completed a large-scale Phase 2/3 clinical trial, and is in a supportive clinical trial in ragweed allergic children; HEPLISAV(TM), a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.
|
DVAX:
This call was made
on 06/27/09
@ $1.38
| Rating: |
$1.38 (06/27/09)
|
| Gain/Loss: |
-6.52%
in
148 days
|
| Target: |
$2.00
(+44.93%)
in > one year
|
| Allocation: |
0.0% of portfolio
|
|
